Denali Therapeutics Inc (DNLI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.90B
Last updated: Nov 17, 2026 at 4:20 PM ET
Denali Therapeutics Inc (DNLI) Statistics
Denali Therapeutics (DNLI) has a market cap of $2.90B and an enterprise value of $2.80B. It kept -1470.50% of revenue as net income over the last 12 months. Its share count is up 9.26% from a year earlier.
Total Valuation
Enterprise value is 3.55% below the market cap, as cash exceeds debt.
| Market Cap | $2.90B |
|---|---|
| Enterprise Value | $2.80B |
| Latest price (Nov 17, 2026) | $18.00 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 158.6x and 3.7x. Its year-end P/S ranged from 3.3x to 111.4x from 2017 to 2023.
| P/S Ratio | 158.6x |
|---|---|
| Forward P/S | 53.8x |
| P/B Ratio | 3.7x |
| P/TBV Ratio | 3.8x |
Price Statistics
The stock is up 3.21% over 52 weeks and trades 8.21% below its 50-day average.
| Beta (1Y) | 1.51 |
|---|---|
| 52-Week Change | +3.21% |
| 1-Month Change | -0.22% |
| 3-Month Change | -29.93% |
| 6-Month Change | -0.61% |
| 5-Year Change | -60.83% |
| Total Return (1Y) | +3.21% |
| Total Return (3Y CAGR) | -1.37% |
| Total Return (5Y CAGR) | -17.50% |
| Return vs SPY (1Y) | -8.58% |
| Max Drawdown (1Y) | -35.28% |
| Max Drawdown (3Y) | -63.68% |
| Sharpe Ratio (1Y) | 0.05 |
| Correlation with SPY (1Y) | 0.38 |
| 50-Day Average | $19.61 |
| 200-Day Average | $21.18 |
| 52-Week Range | $15.34 to $27.30 |
| RSI (14 Days) | 38.7 |
| Average Volume (20 Days) | 1.49M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.21x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.21x |
|---|---|
| Quick Ratio | 5.94x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -33.94% over the last 12 months, against a 5-year average of -32.10%.
| Return on Equity (ROE) | -33.94% |
|---|---|
| Return on Assets (ROA) | -25.03% |
| ROE (5Y Average) | -32.10% |
| ROA (5Y Average) | -26.23% |
| ROIC (5Y Average) | -54.78% |
| Asset Turnover | 0.02x |
| Inventory Turnover | 0.02x |
| Receivables Turnover | 1.87x |
| Cash Conversion Cycle | 3337 days |
Scores
DNLI has an Altman Z-Score of 3.28, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.28 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $21.38M over the last 12 months.
| Revenue | $21.38M |
|---|---|
| Gross Profit | $18.23M |
| Operating Income | -$532.01M |
| Pretax Income | -$314.32M |
| Net Income | -$314.42M |
| Reported EPS (TTM) | -$2.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 73.52% of the $1.26B in total assets.
| Cash and Equivalents | $102.87M |
|---|---|
| Total Debt | $0 |
| Net Cash | $102.87M |
| Net Cash Per Share | $0.55 |
| Working Capital | $496.45M |
| Shareholder Equity | $926.39M |
| Book Value Per Share | $4.92 |
| Tangible Book Value | $891.89M |
| Tangible Book Per Share | $4.73 |
| Total Assets | $1.26B |
| Total Liabilities | $329.65M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.80M of capital spending, operating cash flow left -$449.99M of free cash flow.
| Operating Cash Flow | -$444.19M |
|---|---|
| Capital Expenditures | $5.80M |
| Free Cash Flow | -$449.99M |
| FCF Per Share | -$2.82 |
| Depreciation and Amortization | $16.52M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2488.14%.
| Gross Margin | 85.26% |
|---|---|
| Operating Margin | -2488.14% |
| Pretax Margin | -1470.03% |
| Net Margin | -1470.50% |
| FCF Margin | -2104.54% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -11.98% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -11.98% |
Dividends and Yields
DNLI does not pay a dividend. Its free cash flow yield is -13.27%.
| FCF Yield | -13.27% |
|---|---|
| Buyback Yield | -6.76% |
| Shareholder Yield | -6.76% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DNLI
What is DNLI's market cap?
Denali Therapeutics has a market cap of $2.90B. Its enterprise value, which adds debt and subtracts cash, is $2.80B.
How many shares of DNLI are outstanding?
Denali Therapeutics has 188.39M shares outstanding. The count is up 9.26% from a year earlier.
Does DNLI pay a dividend?
No. Denali Therapeutics does not pay a dividend.
How much debt does DNLI have?
Denali Therapeutics has $0 of total debt and $102.87M of cash and equivalents, a net cash position of $102.87M.
DNLI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors